Navigation Links
Campbell Alliance Clinical Development Practice to Present Session on Global EDC Rollout at Clinical Trials Congress, Europe
Date:5/14/2008

RALEIGH, N.C., and LONDON, May 14 /PRNewswire/ -- Campbell Alliance, the leading management consulting firm specializing in the pharmaceutical and biotech industry, today announced that Gary Tyson, Senior Vice President of the firm's Clinical Development Practice, will present a session on managing the global rollout of electronic data capture (EDC) systems at Informa's Clinical Trials Congress, Europe. The event will be held on May 28-29, 2008, at the Olympia Conference Centre in London.

Mr. Tyson's session, titled "After EDC Implementation: Now What?" is slated for 29 May at 14:50. The session, designed to help clinical leaders understand how organizations can ensure successful uptake of EDC solutions and maximize returns on EDC investments, will cover
-- Performing required organizational changes

-- Implementing continuous process improvement

-- Integrating reporting systems for serious adverse events

-- Integrating other e-clinical systems with EDC

"Although the initial rollout of a clinical EDC solution can be cause for celebration, it doesn't mean that the work is over," Mr. Tyson said. "To fully realize the potential benefits of EDC, clinical organizations must properly integrate key activities and processes with the system."

As head of Campbell Alliance's Clinical Development Practice, Gary Tyson leads a team that provides a range of operational improvement services to clinical development organizations within pharmaceutical and biotech companies, as well as leading contract research organizations (CROs). Mr. Tyson is a veteran of numerous EDC-related initiatives, including helping organizations adopt EDC at the enterprise level, and brings a wealth of knowledge and experience in process improvement, organizational design, and clinical development to his consulting engagements.

For more information on Informa's Clinical Trials Congress, Europe, please visit

SOURCE Campbell Alliance
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Campbell Alliance to Moderate Senior-Level Panel Discussion at Windhover Pharmaceutical Strategic Alliances Conference
2. Campbell Alliance Managed Markets Practice to Take Leadership Role at CBIs Formulary and Reimbursement Conference
3. Campbell Alliance Named Best Place to Work by Triangle Business Journal
4. Campbell Alliance Business Development Practice to Moderate Two Workshops at LES Annual Meeting in Vancouver
5. Campbell Alliance Launches New Practice Area Focused on Trade and Distribution
6. Campbell Alliance Trade and Distribution Practice to Chair CBI 3rd Annual Fee for Service and EDI Data Management Conference
7. Campbell Alliance Brand Management Practice to Discuss Managing Launch Logistics at the EyeForPharma Oncology Summit
8. Campbell Alliance Brand Management and Managed Markets Practices to Speak at CBIs Early Commercialization Conference
9. Campbell Alliance Sales Practice to Conduct Workshop at EyeForPharma SFE Europe Conference
10. Campbell Alliance Managed Markets Practice to Take a Leadership Role at the CBI Forum on Effective Product Pricing and Modeling Strategies
11. Campbell Alliance Adds Doug Linton, Former Cardinal Health Executive, to Executive Advisory Group
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... DUBLIN , Sep. 02, 2015 ... ) has announced the addition of Jain PharmaBiotech,s ... Companies" to their offering. This ... as a characteristic that can be objectively measured ... or pathogenic processes as well as pharmacological responses ...
(Date:9/2/2015)... Sept. 2, 2015  Neurotech Pharmaceuticals, Inc., announced ... the multicenter Phase 2 clinical trial of NT-503 ... of recurrent subfoveal choroidal neovascularization secondary to age ... unique vascular endothelial growth factor (VEGF) receptor protein ... "This landmark proof-of-concept study will evaluate NT-503 ...
(Date:9/2/2015)... ZIONA, Israel , September 2, 2015 ... BVXV) today announced the intent of the National Institute of ... Institutes of Health (NIH) within the Department of Health and ... to be held in the United States ... use of BiondVax,s universal flu vaccine candidate, Multimeric-001 (M-001), as ...
(Date:9/2/2015)... ... 02, 2015 , ... The TS5-Q is designed for myriad ... to analysis of athletic performance. Producing high-resolution slow-motion video , the TS5-Q ... process with the naked eye. , Slow motion sequences are commonly seen ...
Breaking Biology Technology:Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 2Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 2BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 3Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 2Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 3
... race to make solar cells cheaper and more ... on new designs that exploit nanostructures--materials engineered on ... Using nanotechnology, researchers can experiment with and control ... free electrons--properties that are important for the conversion ...
... 8 RxElite, Inc. (OTC,Bulletin Board: RXEI), a ... products, announced today that as permitted under,the registration ... stockholders to cease using the company,s Registration Statement ... 2008 prospectus until,further advised. This release corrects and ...
... expands SRA footprint in human health services around the ... ... overall,expansion in new markets, SRA International, Inc. (NYSE: SRX ) today,announced the ... President and Chief Financial Officer (CFO) of its new,Global Health Sector (GHS) organization. ...
Cached Biology Technology:New nanostructured thin film shows promise for efficient solar energy conversion 2New nanostructured thin film shows promise for efficient solar energy conversion 3/CORRECTION//- RxElite Temporarily Suspends Sales Under Its Registration Statement 2SRA Names Timothy J. Atkin Senior Vice President of Global Health Business; Appoints Mike Toner Global Health Unit Chief Financial Officer 2SRA Names Timothy J. Atkin Senior Vice President of Global Health Business; Appoints Mike Toner Global Health Unit Chief Financial Officer 3
(Date:8/19/2015)... 2015  VOXX International Corporation (Nasdaq: VOXX ... a Definitive Agreement to purchase the assets, inclusive ... leader EyeLock through an acquiring entity.  Upon consummation ... interest in the acquiring entity. The closing of ... diligence.  Expanding on its existing supply chain and ...
(Date:8/18/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/9dmm6l/global_biometric ... "Global Biometric Authentication & Identification Market: Focus On ... 2015-2020" report to their offering. ... market is expected to grow at an estimated ... generate over $25 billion (approximately) by 2020 as ...
(Date:8/12/2015)... MINNETONKA, Minn. , Aug. 12, 2015   ... that supports the entire spectrum of clinical research, is ... ™ , the company,s comprehensive SaaS-based eClinical technology platform, ... growth during the first two quarters of 2015.   ... and second largest quarters measured by contract value sold ...
Breaking Biology News(10 mins):VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2MedNet Solutions Experiences Explosive Corporate Growth 2
... have uncovered a new cellular secret that may explain ... of cancers that makes treatment especially difficult. If the ... -- can be understood well enough to manipulate it, ... with metastatic cancers. , Significance of the Mayo ...
... exposure has already permanently damaged their skin cells, causing ... dark splotches and uneven skin tone over time. But ... known for treating arthritis ?can actually help stop the ... ones. , "These findings on glucosamine may impact the ...
... have taken a potentially powerful new therapy for treating ... the test tube and into animals by demonstrating it ... The research has particularly important implications for the estimated ... both nerves and blood vessels. , The therapy involves ...
Cached Biology News:Mayo Clinic researchers discover cancer cells may move via wave stimulation 2Mayo Clinic researchers discover cancer cells may move via wave stimulation 3Science finds new fix for UV-damaged skin in arthritis treatment 2Science finds new fix for UV-damaged skin in arthritis treatment 3Proteins spur diabetic mice models to grow blood vessels, nerves 2
... can be upgraded to the GenePix Autoloader ... analyzes, and saves results for up to ... when the batch is complete. Line-by-line autofocus ... slides. GenePix Pro gives you complete flexibility ...
... a fast, easy to use, reproducible and ... are 15 times faster and 5 times ... 5%). ,The VoluPAC tubes enable the determination ... a cell suspension, resulting in absolute data ...
... your microarray data using Asuragens bioinformatics expertise. ... consultation to extensive data analysis using the ... expertise in combination with the Gene Expression ... experiments., ,Normalization and basic statistical analysis including ...
... This CLS number is a ... easily match Cornings product number. ... please order under the old ... customer service for assistance. ...
Biology Products: